Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: Implications for risks of transmission

Journal of Infectious Diseases

Volumn 209, Issue 8, 2014, Pages 1205-1211

  Paintsil, Elijah ^a   Binka, Mawuena ^b   Patel, Amisha ^b   Lindenbach, Brett D ^a   Heimer, Robert ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

fomites; hepatitis C virus; infectivity; nosocomial; transmission; virucidal agents

Indexed keywords

ALCOHOL; BLEACHING AGENT; DISINFECTANT AGENT;

ARTICLE; CONTROLLED STUDY; FOMITE; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; STORAGE TEMPERATURE; SURFACE PROPERTY; VIRAL CONTAMINATION; VIRUS INFECTIVITY; VIRUS TRANSMISSION; VIRUS VIABILITY;

FOMITES; HEPATITIS C VIRUS; INFECTIVITY; NOSOCOMIAL; TRANSMISSION; VIRUCIDAL AGENTS;

CELL CULTURE TECHNIQUES; CROSS INFECTION; FOMITES; HEPACIVIRUS; HEPATITIS C; HUMANS; MICROBIAL VIABILITY; RISK; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS;

EID: 84897427632     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit648     Document Type: Article

References (43)

1. Cohen J. The scientific challenge of hepatitis C. Science 1999; 285: 26-30.
2. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93-98.
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
4. Paintsil E, Verevochkin SV, Dukhovlinova E, et al. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: Social and molecular epidemiology of an endemic infection. Addiction 2009; 104:1881-90.
5. Tosti ME, Solinas S, Prati D, et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol 2002; 117:215-9.
6. Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005; 19:S20-25.
7. Stark K, Herrmann U, Ehrhardt S, Bienzle U. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Epidemiol Infect 2006; 134: 814-9.
8. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34:180-7.
9. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence?. Model projections for different epidemic settings. Addiction 2012; 107:1984-95.
10. Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill 2011; 16:1-5.
11. Blome MA, Bjorkman P, Flamholc L, Jacobsson H, Molnegren V, Widell A. Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program. J Viral Hepat 2011; 18:831-9.
12. Holtzman D, Barry V, Ouellet LJ, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med 2009; 49:68-73.
13. Deterding K,Wiegand J, Gruner N,Wedemeyer H. Medical procedures as a risk factor for HCV infection in developed countries: Do we neglect a significant problem in medical care?. J Hepatol 2008; 48:1019-20.
14. Desenclos JC, Bourdiol-Razes M, Rolin B, et al. Hepatitis C in a ward for cystic fibrosis and diabetic patients: Possible transmission by springloaded finger-stick devices for self-monitoring of capillary blood glucose. Infect Control Hosp Epidemiol 2001; 22:701-7.
15. Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 2005; 142:898-902.
16. Forns X, Martinez-Bauer E, Feliu A, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005; 41:115-22.
17. Krause G, Trepka MJ, Whisenhunt RS, et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol 2003; 24:122-7.
18. Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community-Acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43:1154-9.
19. Martinez-Bauer E, Forns X, Armelles M, et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008; 48:20-7.
20. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: Implication for transmission among injection drug users. J Infect Dis 2010; 202:984-90.
21. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-6.
22. Lindenbach BD, Meuleman P, Ploss A, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci 2006; 103:3805-9.
23. Reed LJ, Muench H. A simple method of estimating fifty percent end points. Am J Hyg 1938; 27:493-7.
24. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76:13001-14.
25. Prince H. Disinfectant activity against bacteria and viruses: A hospital guide. Particulate & Microbial Control 1983:55-62.
26. Disinfectants for Use on Hard Surfaces. In efficacy data requirements. In: DIS/TSS-1 Jan 22, 1982. USA: EPA. http://www.epa.gov/oppad001/dis-tss-docs/ dis-01.htm. Accessed 5 October 2013.
27. Laboratory Biosafety Manual. Third Edition. Geneva: World Health Organization. 2004. http://www.who.int/csr/resources/publications/biosafety/WHO- CDS-CSR-LYO-2004-11/en/. Accessed 5 October 2013.
28. Doerrbecker J, Friesland M, Ciesek S, et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis 2011; 204:1830-8.
29. Ciesek S, Friesland M, Steinmann J, et al. How stable is the hepatitis C virus (HCV)?. Environmental stability of HCV and its susceptibility to chemical biocides. J Infect Dis 2010; 201:1859-66.
30. Sattar SA, Springthorpe VS, Adegbunrin O, Zafer AA, Busa M. A discbased quantitative carrier test method to assess the virucidal activity of chemical germicides. J Virol Methods 2003; 112:3-12.
31. Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol 2007; 28:519-24.
32. Doerrbecker J, Meuleman P, Kang J, et al. Thermostability of seven hepatitis C virus genotypes in vitro and in vivo. J Viral Hepat 2013; 20:478-85.
33. van Bueren J, Simpson RA, Jacobs P, Cookson BD. Survival of human immunodeficiency virus in suspension and dried onto surfaces. J Clin Microbiol 1994; 32:571-4.
34. Barre-Sinoussi F, Nugeyre MT, Chermann JC. Resistance of AIDS virus at room temperature. Lancet 1985; 2:721-2.
35. Bean B, Moore BM, Sterner B, Peterson LR, Gerding DN, Balfour HH Jr. Survival of influenza viruses on environmental surfaces. J Infect Dis 1982; 146:47-51.
36. Hall CB, Douglas RG Jr., Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980; 141:98-102.
37. Damjanovic V. What makes human immunodeficiency virus (HIV) resistant to dry heat inactivation?. J Hosp Infect 1987; 10:209-11.
38. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981; 1:550-1.
39. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91:42-6.
40. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. J Infect Dis 2002; 186:1558-64.
41. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155:645-53.
42. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006; 101:1499-508.
43. Roy E, Arruda N, Leclerc P, Haley N, Bruneau J, Boivin JF. Injection of drug residue as a potential risk factor for HCV acquisition among Montreal young injection drug users. Drug Alcohol Depend 2012; 126:246-50.